갑상선유두암에서 Galectin-3, p53, Ki-67 단백질의 발현과 임상학적 의미

Purpose: There are few molecular markers useful in practice for predicting prognosis of papillary thyroid carcinoma (PTC) despite numerous basic researches. The objective of this study was to evaluate the prognostic values of several candidate markers of PTC (p53, Ki-67 and galectin-3) using immunohistochemistry (IHC), one of the most practical methods. Methods: IHC for p53, Ki-67 and galectin-3 were performed on formalin-fixed paraffin-embedded tissues of 160 PTC specimens using monoclonal antibodies. The associations of the expressions of these markers with multiple clinicopathologic prognostic factors were assessed. Results: The overexpresion rates of p53, Ki-67 and galectin-3 were 48.8%, 64.3% and 97.8%, respectively. Overexpression of p53 protein was positively associated with extrathyroidal extension (P＜0.001). In addition, p53 immunoreactivity was more prevalent among Ki-67 overexpressed specimens (P＜0.001). Ki-67 immunoreactivity was positively correlated with tumor size (P＜0.05), which became more distinct when accompanied with p53 overexpression (P＜0.01). In contrast, no relationship between galectin-3 immunoreactivity and clinical prognostic factors was found. Conclusion: Our results suggest that overexpression of p53 protein and Ki-67 in papillary thyroid carcinoma is associated with tumor progression and that IHC for these proteins could be useful for predicting prognosis of patients with PTC.

[1]  M. Choi,et al.  Proximal Splenic Artery Pseudoaneurysm after Radical Subtotal Gastrectomy , 2009 .

[2]  Byung Ki Kim,et al.  A Rare Ileal Intussusception Caused by a Lipoma of the Ileum , 2009 .

[3]  A. Raz,et al.  The role of galectin-3 in cancer drug resistance. , 2007, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[4]  Jinhwan Kim,et al.  Clinical Significance of the Expression of Galectin-3 in Thyroid Tumor , 2006 .

[5]  D. Coppola,et al.  Role of p53, CD44V6 and CD57 in differentiating between benign and malignant follicular neoplasms of the thyroid. , 2004, In vivo.

[6]  N. Farid.  P53 mutations in thyroid carcinoma: Tidings from an old foe , 2001, Journal of endocrinological investigation.

[7]  T. Dobosz,et al.  Microsatellite Instability in Thyroid Papillary Carcinoma and Multinodular Hyperplasia , 2000, Oncology.

[8]  D. Heo,et al.  Correlation between Clinical Outcome and Proliferation Index in Diffuse Large B-Cell Lymphoma , 1999 .

[9]  C. Yeo.  Tumor suppressor genes: a short review. , 1999, Surgery.

[10]  G. Pelosi,et al.  Ki‐67 immunostaining in 322 primary breast cancers: Associations with clinical and pathological variables and prognosis , 1997, International journal of cancer.

[11]  S. Asa,et al.  Immunohistochemical localization of p53 in human thyroid neoplasms: Correlation with biological behavior , 1997, Endocrine pathology.

[12]  C. Larsson,et al.  Alterations of p53 and expression of WAF1/p21 in human thyroid tumors. , 1996, Thyroid : official journal of the American Thyroid Association.

[13]  A. Levine,et al.  The p53 tumour suppressor gene , 1991, Nature.

[14]  K. Gatter,et al.  Monoclonal antibody Ki‐67: its use in histopathology , 1990, Histopathology.

[15]  I. Hay.  Papillary thyroid carcinoma. , 1990, Endocrinology and metabolism clinics of North America.

[16]  F. Collins,et al.  Mutations in the p53 gene occur in diverse human tumour types , 1989, Nature.